A phase I prospective, single dose, double blinded, parallel group pharmacokinetic study of TX16 biosimilar product TX16.

Trial Profile

A phase I prospective, single dose, double blinded, parallel group pharmacokinetic study of TX16 biosimilar product TX16.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Feb 2018 New trial record
    • 17 Jan 2018 According to a Tanvex BioPharma media release, the company has completed the trial last year.
    • 19 Dec 2017 Primary endpoint AUC 0-infinity has been met, according to Tanvex BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top